Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Shaughnessy

Showing results (151-160 of 194) with videos related to

Pageof 20
Sort By:
Blood|May 18, 2006
Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantationIchiro Hanamura, James P Stewart, Yongsheng Huang, et al.
JAMA Oncology|June 5, 2025
Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols: A Secondary Analysis of 3 Clinical TrialsSamer Al Hadidi, Obada Ehab Ababneh, Carolina D Schinke, et al.
Haematologica|October 2, 2010
Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myelomaDirk Hose, Thierry Rème, Thomas Hielscher, et al.
Oncogene|April 12, 2011
Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cellsU-M Fagerli, K Ullrich, T Stühmer, et al.
Blood|May 31, 2007
The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapyYang Yang, Veronica MacLeod, Yuemeng Dai, et al.
Blood Advances|December 5, 2023
Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-upSamer Al Hadidi, Obada Ehab Ababneh, Carolina D Schinke, et al.
Blood|August 2, 2008
Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic diseaseBart Barlogie, Frits van Rhee, John D Shaughnessy, et al.
Blood|February 21, 2009
The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptorAnne Catherine Sprynski, Dirk Hose, Laurent Caillot, et al.
Blood|June 2, 2011
Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3John D Shaughnessy, Pingping Qu, Saad Usmani, et al.
The Journal of Clinical Investigation|June 1, 2021
TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignanciesCan Li, Jiliang Xia, Reinaldo Franqui-Machin, et al.
Pageof 20

Showing results (151-160 of 194) with videos related to

Sort By:
Pageof 20
Blood|May 18, 2006
Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantationIchiro Hanamura, James P Stewart, Yongsheng Huang, et al.
JAMA Oncology|June 5, 2025
Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols: A Secondary Analysis of 3 Clinical TrialsSamer Al Hadidi, Obada Ehab Ababneh, Carolina D Schinke, et al.
Haematologica|October 2, 2010
Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myelomaDirk Hose, Thierry Rème, Thomas Hielscher, et al.
Oncogene|April 12, 2011
Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cellsU-M Fagerli, K Ullrich, T Stühmer, et al.
Blood|May 31, 2007
The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapyYang Yang, Veronica MacLeod, Yuemeng Dai, et al.
Blood Advances|December 5, 2023
Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-upSamer Al Hadidi, Obada Ehab Ababneh, Carolina D Schinke, et al.
Blood|August 2, 2008
Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic diseaseBart Barlogie, Frits van Rhee, John D Shaughnessy, et al.
Blood|February 21, 2009
The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptorAnne Catherine Sprynski, Dirk Hose, Laurent Caillot, et al.
Blood|June 2, 2011
Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3John D Shaughnessy, Pingping Qu, Saad Usmani, et al.
The Journal of Clinical Investigation|June 1, 2021
TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignanciesCan Li, Jiliang Xia, Reinaldo Franqui-Machin, et al.
Pageof 20